Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

cacy of 28- and 48-week lead-in regimens of boceprevir (800 mg TID) in combination with PEGINTRON (1.5 mcg/kg/week) and REBETOL (600-1400 mg/day) compared to a control of PEGINTRON and REBETOL alone for 48 weeks in treatment-naive adult patients with chronic HCV genotype 1. The study enrolled a total of 1,099 patients, including 158 African-American/Black patients.

The HCV RESPOND-2 study evaluates 36- and 48-week lead-in regimens of boceprevir in combination with PEGINTRON and REBETOL at the same doses as described above compared to a control of PEGINTRON and REBETOL alone for 48 weeks in adult patients with chronic HCV genotype 1 who failed prior treatment (relapsers and nonresponders) with peginterferon and ribavirin combination therapy. The study enrolled a total of 404 patients.

In both registration studies, RVR criteria at 4 weeks of boceprevir treatment (treatment week 8) is used to determine which boceprevir patients can stop all treatment at 28 weeks (HCV SPRINT-2) or 36 weeks (HCV RESPOND-2).

For more information about ongoing studies, please visit www.clinicaltrials.gov, search term boceprevir or SCH 900518.

About Hepatitis C

Hepatitis C is a serious and potentially life-threatening disease. It is the most common blood-borne infection in America and Europe, and the most common form of liver disease, affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe.

About PEGINTRON

PEGINTRON is indicated for use in combination with REBETOL (ribavirin) for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease.

The following
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  TechAtlas Group has announced the release of ... for the Chronic Kidney Disease (CKD) market. This ... drugs and devices currently on the market and ... (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... renal denervation , diabetic nephropathy - antifibrotics ...
(Date:5/17/2013)... MIAMI LAKES, Fla. , May 17, 2013 ... products and delivery technology company that is developing new, patent-pending ... and minerals, announced today that it will hold a business ... on Wednesday, May 22 nd , 2013 at 4:30 PM ... Brian Tuffin will host the call and will ...
(Date:5/17/2013)... , May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... study, JAKARTA , examining the selective ... endpoint in both dose groups. The primary endpoint assessed ... volume. Consistent with data reported in previous trials, the ... vomiting. Full results will be presented at an upcoming ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
(Date:5/20/2013)... May 20, 2013 Widely regarded as ... genital plastic surgery and women’s sexual health, Dr. Goodman ... Board of http://www.labiaplastysurgeon.com , the nationally ranked ... proud to be a member of this informative and ... the appointment. “I’ve already worked with the President ...
(Date:5/20/2013)... May 20, 2013 AURORA, Colo. – ... online accredited university, has developed a Bachelor of ... assess how they feel about continuing their education and ... print out the complimentary worksheet, respond to ten statements ... they rate on a BSN-readiness scale. , New industry ...
(Date:5/20/2013)... Columbus, OH (PRWEB) May 20, 2013 ... an experienced medical device law firm, report that two ... the coming months in state and federal litigations established ... On June 11th, the first C.R. Bard bellwether trial ... Court, Southern District of West Virginia. (In re: ...
(Date:5/20/2013)... Durham, N.C. (PRWEB) May 20, 2013 ... Training Institute (IFPTI), will speak at North Carolina Food ... Food is Good Business: The Need for Partnerships – ... , The two-day conference, scheduled for May 22-23 at ... role partnerships across the food sector have in protecting ...
(Date:5/19/2013)... Houston,TX (PRWEB) May 20, 2013 Due ... companies with online advertising, MileageAds.com has decided to invite ... advertisements through their ad network. , Businesses in ... of success with online marketing, specifically with ad networks. ... advice, information and legal services and are unsure where ...
Breaking Medicine News(10 mins):Health News:Globally Respected Feminine Cosmetic Genital Surgeon Joins Board of Industry Leading Labiaplasty Medical Website 2Health News:Globally Respected Feminine Cosmetic Genital Surgeon Joins Board of Industry Leading Labiaplasty Medical Website 3Health News:American Sentinel University Develops New Worksheet to Help Nurses Determine BSN-Readiness 2Health News:American Sentinel University Develops New Worksheet to Help Nurses Determine BSN-Readiness 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 2Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 4Health News:IFPTI Executive Director to Speak at North Carolina Food Safety and Defense Task Force Annual Conference 2Health News:Mileageads Ad Network Now Invites Bloggers and Business Owners in Mesothelioma Sector to Advertise on Their Ad Network 2
... solutions to tackle obesity, the latest on the Northwick ... sport and the Olympics will be highlighted at ... Pharmacological Society (BPS), Europe,s leading pharmacological research society, is ... attracting experts from across the world. , Running from ...
... Public Relations Worldwide (Ogilvy PR), an integrated global communications ... five-year comprehensive communications support contract with the National Cancer ... will be performed by Ogilvy PR,s Washington, DC-based Social ... consulting subsidiary, Feinstein Kean Healthcare (FKH). , ...
... But American physicians often overlook the illness, delaying diagnosis ... doctors view leprosy as a scourge of Biblical times ... U.S. cases, with more diagnosed each year, experts say. ... remains a largely forgotten illness, U.S. physicians are often ...
... peginterferon in combination with ribavirin for previously untreated children ... , KENILWORTH, N.J., Dec. ... today announced that the U.S. Food and Drug Administration ... and REBETOL(R) (ribavirin, USP) combination therapy for use in ...
... ANN ARBOR, Mich., Dec. 12 Terumo Corporation ... that,they have entered into an agreement to settle ... companies have a number of lawsuits pending,in which ... The litigations all,involve methods and devices used ...
... Dec. 12 Dignitas Personae (The Dignity of ... Doctrine of the Faith (CDF) on ethical issues arising from ... and human procreation in our heavily scientific age, said Cardinal ... of Catholic Bishops. , , ...
Cached Medicine News:Health News:Leading pharmacologists to meet in Brighton 2Health News:National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support 2Health News:Leprosy Lingers in the U.S. 2Health News:Leprosy Lingers in the U.S. 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 2Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 3Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 4
The entirely open modular system is especially suitable for stereotactic microsurgical procedures....
Used to negotiate tortuous vessels....
The Emerald Guidewire is intended for percutaneous introduction of catheters....
... The MULTI-LINK VISION Coronary Stent System is ... cobalt chromium stents. Cobalt chromium is stronger ... a cobalt chromium stent can have similar ... steel stent with struts that are only ...
Medicine Products: